Hemab is developing bispecific antibodies that bind and stabilize endogenous clotting factors to create the first prophylactic treatments for rare bleeding and thrombotic disorders, such as Glanzmann Thrombasthenia and Factor VII Deficiency. This approach addresses the lack of preventative therapies for these underserved conditions, providing patients with a means to form healthy clots and reduce the risk of life-threatening complications.
Funding
$196M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare bleeding and thrombotic disorders currently lack preventative treatment options, leaving them vulnerable to unpredictable and potentially life-threatening bleeding or thrombotic events. Existing treatments primarily address common clotting disorders, leaving a significant unmet need for prophylactic therapies for less-common, genetically driven conditions.
Solution
Hemab is developing targeted preventative treatments and functional cures for a range of rare bleeding and thrombotic disorders. Their approach involves bispecific antibodies that bind and stabilize endogenous clotting factors, enabling the formation of hemostatic plugs at the site of injury. These therapies are designed to modulate and balance the body's native clotting factors, preventing their breakdown and allowing them to accumulate to therapeutic levels. Hemab's therapeutic candidates offer the potential to prevent life-threatening complications and provide patients with a more secure and predictable life.
Target Audience
The primary target audience includes individuals suffering from rare bleeding and thrombotic disorders such as Glanzmann Thrombasthenia, Factor VII Deficiency, and Von Willebrand Disease, as well as the physicians who treat them.
Features
- Bispecific antibodies that bind with high specificity and affinity to the body’s native clotting factors.
- Antibody binding stabilizes native clotting factors, preventing breakdown and allowing accumulation to therapeutic levels.
- Therapies can be designed to be neutral (preserving the activity of the native clotting factor) or inhibitory (inactivating the clotting factor).
- Ability to recruit native clotting factors directly to the site of injury.
- Lead candidate HMB-001 is a bispecific antibody that binds, stabilizes, and recruits endogenous factor VIIa (FVIIa) to the site of vascular injury.
- HMB-002 is designed as a prophylactic treatment for Von Willebrand Disease Type 1 and 2.